Blood spot tests set to replace costly vials

Blood spot tests set to replace costly vials

February 27, 2020

From The Lead South Australia:
Blood testing technology developed by South Australian medical researchers is poised to transform the nutrition industry.

Trajan Nutrition dried blood spot (DBS) card

Trajan Nutrition CEO Marco Baccanti said, “Pathology labs can also now start using this methodology with far less invasive collection of blood of patients and using faster analytics and more cost effective techniques.”

University of Adelaide Professor of Functional Food Science Robert Gibson began work on the technology 10 years ago with Professor Maria Makrides.

“We are one of the leading labs now at developing the new dry blood spot tests for a variety of nutrients and compounds,” Prof Gibson said.

Read the full article: Blood spot tests set to replace costly vials

Trajan Nutrition CEO Marco Baccanti and University of Adelaide Professor of Functional Food Science Robert Gibson.
Trajan Nutrition CEO Marco Baccanti and University of Adelaide Professor of Functional Food Science Robert Gibson.

More information
Trajan Nutrition




Also in News

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More

CE mark for Trajan’s hemaPEN blood microsampling device, now available for diagnostic use across EU and UK
CE mark for Trajan’s hemaPEN blood microsampling device, now available for diagnostic use across EU and UK

May 07, 2020

Trajan Scientific and Medical has declared hemaPEN compliance with EU IVD Directive 98/79/EC, and its release for in vitro diagnostic use in the EU and UK. This follows the hemaPEN’s recent addition to the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class 1 IVD device.

Read More